Evidence map›Paper›PMID 41869309›Full record

ArticleFrontiers in immunology2026

Fang-Fang Shen, Dong-Fen Li, Ling-Bei Kong, Jia-Le Li, Shi-Long Ma, Hao-Zhe Jiang, Hao-Ze Yuan, Yan Jin, Zhi-Guo Chen, Xiu-Juan Guo and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fang-Fang ShenThe Key Laboratory for Tumor Translational Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Dong-Fen LiThe Key Laboratory for Tumor Translational Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Ling-Bei KongThe Key Laboratory for Tumor Translational Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Jia-Le LiThe Key Laboratory for Tumor Translational Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Shi-Long MaThe Key Laboratory for Tumor Translational Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Hao-Zhe JiangThe Key Laboratory for Tumor Translational Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Hao-Ze YuanThe Key Laboratory for Tumor Translational Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Yan JinSchool of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China.
Zhi-Guo ChenSchool of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China.
Xiu-Juan GuoThe Key Laboratory for Tumor Translational Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Gao-Pan DongSchool of Pharmacy, Xinxiang Medical University, Xinxiang, Henan, China.
De-Rong LuDepartment of Gastroenterology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Jia-Teng ZhongDepartment of Pathology, Xinxiang Medical University, Xinxiang, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Metastatic recurrence drives dismal survival in esophageal squamous cell carcinoma (ESCC), yet epigenetic mechanisms underlying metastasis remain poorly defined. While DNMT1 and DNMT3A contribute to ESCC pathogenesis, DNMT3B's role is enigmatic despite frequent dysregulation. Methods: Integrated methylome-transcriptome profiling comprised genome-wide methylation screening in 5 paired ESCC tumor and adjacent normal tissues. Parallel mRNA microarray profiling quantified expression levels of Results: Discussion:

Indexed as

ADAMTS9 ProteinCell Adhesion MoleculesDNA (Cytosine-5-)-MethyltransferasesEpigenesis, GeneticEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaAnimalsCell Line, TumorCell MovementCell ProliferationDNA MethylationDNA Methyltransferase 3BGene Expression Regulation, NeoplasticGene SilencingHumansMaleADAMTS9 ProteinCADM2 protein, humanCell Adhesion MoleculesDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3BADAMTS9-AS2CADM2DNMT3Bepigenetic therapyesophageal squamous cell carcinomametastasis

Identifiers

PMID41869309
PMCPMC13003458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.